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Blood pressure variability and cardiovascular disease:  
systematic review and meta-analysis
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Richard J McManus1 
ABSTRACT
ObjeCtive
To systematically review studies quantifying the 
associations of long term (clinic), mid-term (home), 
and short term (ambulatory) variability in blood 
pressure, independent of mean blood pressure, with 
cardiovascular disease events and mortality.
Data sOurCes
Medline, Embase, Cinahl, and Web of Science, 
searched to 15 February 2016 for full text articles in 
English.
eligibility Criteria fOr stuDy seleCtiOn
Prospective cohort studies or clinical trials in adults, 
except those in patients receiving haemodialysis, 
where the condition may directly impact blood 
pressure variability. Standardised hazard ratios were 
extracted and, if there was little risk of confounding, 
combined using random effects meta-analysis in main 
analyses. Outcomes included all cause and 
cardiovascular disease mortality and cardiovascular 
disease events. Measures of variability included 
standard deviation, coefficient of variation, variation 
independent of mean, and average real variability, but 
not night dipping or day-night variation.
results
41 papers representing 19 observational cohort studies 
and 17 clinical trial cohorts, comprising 46 separate 
analyses were identified. Long term variability in blood 
pressure was studied in 24 papers, mid-term in four, 
and short-term in 15 (two studied both long term and 
short term variability). Results from 23 analyses were 
excluded from main analyses owing to high risks of 
confounding. Increased long term variability in systolic 
blood pressure was associated with risk of all cause 
mortality (hazard ratio 1.15, 95% confidence interval 
1.09 to 1.22), cardiovascular disease mortality (1.18, 
1.09 to 1.28), cardiovascular disease events (1.18, 1.07 
to 1.30), coronary heart disease (1.10, 1.04 to 1.16), and 
stroke (1.15, 1.04 to 1.27). Increased mid-term and 
short term variability in daytime systolic blood 
pressure were also associated with all cause mortality 
(1.15, 1.06 to 1.26 and 1.10, 1.04 to 1.16, respectively).
COnClusiOns
Long term variability in blood pressure is associated 
with cardiovascular and mortality outcomes, over and 
above the effect of mean blood pressure. Associations 
are similar in magnitude to those of cholesterol 
measures with cardiovascular disease. Limited data 
for mid-term and short term variability showed similar 
associations. Future work should focus on the clinical 
implications of assessment of variability in blood 
pressure and avoid the common confounding pitfalls 
observed to date.
systematiC review registratiOn
PROSPERO CRD42014015695.
Introduction
Blood pressure is a leading risk factor for cardiovascu-
lar disease.1 2  Most studies have used mean blood pres-
sure as the indicator of risk, measured in clinic or “out 
of office” settings.3-5  However, blood pressure shows 
noticeable oscillations over the short and long term.6 
Historically, variability in blood pressure has been 
viewed as inhibiting accurate measurement of mean 
blood pressure and as a phenomenon to be overcome 
by improved monitoring.7  For at least two decades, this 
variability has also been recognised as a potential risk 
factor in its own right.8 9  In 2010 an analysis of three 
cohort studies and two randomised trials found that 
long term variability in blood pressure was a predictor 
of stroke and coronary events in high risk patients.10
However, understanding this variability has been 
hampered by statistical and clinical methodological 
problems. Some analyses of variability have not 
adjusted for mean blood pressure, potentially con-
founding high variability with high mean blood pres-
sure,11  or have adjusted for a mean that is not fully 
consistent with the variability measure.12  Others, in 
using 24 hour mean to adjust for daytime variability, 
might have turned high daytime variability into a surro-
gate marker for nocturnal or 24 hour blood pressure.13 
Further studies have defined variability on the basis of 
measurements taken during follow-up, but analysed it 
as a baseline risk factor,14-16  potentially introducing 
problems of informative censoring or immortal time 
bias.17 Informative censoring occurs when reasons for 
loss to follow-up are confounded with the exposure 
WhAT IS AlReAdy knoWn on ThIS TopIC
It is well established that patients with high blood pressure are at higher risk of 
future cardiovascular disease
Some studies have also suggested that patients with higher variability in blood 
pressure over time are at higher risk compared with patients with the same mean 
blood pressure level
It is not clear whether this risk depends on the method of measurement of variability, 
and few have correctly accounted for mean blood pressure or changes in  treatment
WhAT ThIS STudy AddS
Methodological errors are present in approximately half of prospective studies of 
blood pressure variability, but the association of long term (clinic) variability in blood 
pressure with future cardiovascular disease is found even in studies that avoid errors
Mid-term and short term variability in blood pressure measured at home or by 
ambulatory monitoring, respectively, has been little studied comparatively, but 
shows similar associations with outcomes
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(eg, if individuals with extreme or erratic blood pres-
sures are withdrawn from studies because of concerns 
about safety). Immortal time bias can occur if individu-
als are required to have a certain number of blood pres-
sure measurements in order to be included in analysis 
for mortality outcomes. The time up until the qualifying 
measurement becomes “immortal time,” because, by 
definition, death could not occur earlier.
Other studies failed to use consistent blood pressure 
monitoring equipment over time, to define a consistent 
measurement protocol, or to account for change in 
drugs, leaving doubt as to the source of any observed 
variability.14 18 19  Measurement at different times of the 
day20  or year,21  in different arms,22  or using inconsistent 
cuff sizes23 can affect accurate measurement, thereby 
inducing variability. We reviewed prospective studies in 
adults that quantified the associations of blood pres-
sure variability with cardiovascular events and mortal-
ity, independent of mean blood pressure. Our main 
analysis focused on studies meeting prespecified meth-
odological criteria, so that any apparent effect of vari-
ability was likely to be a true independent effect.
Methods
study selection
We searched Medline, Embase, Cinahl, and Web of Sci-
ence to 15 February 2016 for full text articles in English 
describing trials and prospective cohort studies in 
adults that assessed the association of periods of vari-
ability in blood pressure with cardiovascular outcomes 
(see supplementary table e1). Long term variability was 
measured through clinic blood pressure monitoring, 
mid-term through home monitoring, and short term 
through ambulatory monitoring. Studies included in 
recent systematic reviews24-27 were also screened. Two 
reviewers (SW/SS and KL/KC) scrutinised the titles and 
abstracts, with adjudication by a third reviewer (RM).
inclusion and exclusion criteria
Studies had to consider at least one of the following 
outcomes: all cause mortality, cardiovascular events 
(including stroke, myocardial infarction, coronary 
heart disease, and heart failure), or cardiovascular mor-
tality (including sudden death). We excluded studies 
only assessing intermediate outcomes (eg, arterial 
intima media thickness) or concerning nocturnal dip-
ping or day-night variation, as these have been consid-
ered previously.28
Studies in disease specific populations (eg, people 
with diabetes) were included, except those in patients 
receiving haemodialysis where changes in blood pres-
sure (intradialysis hypotension and hypertension29 30) 
are common and have been shown to be associated 
with hospital admission and mortality.31 32
Included studies had at least 2500 person years of 
follow-up. Blood pressure variability was assessed in 
the long term (in clinics), mid-term (at home), or short 
term (through ambulatory monitoring). Studies of clinic 
monitoring had to measure visit-to-visit variability over 
at least five clinic visits. Studies of home monitoring 
had to consider day-by-day variability over at least 12 
measurements on at least three days.33  Studies for 
ambulatory monitoring had to assess variability up to 
24 hours, with at least 14 daytime readings.33
Data extraction
Using prespecified forms, two reviewers (SS/SW and 
KL/RM) independently extracted data on study and 
patient characteristics and two (SS and KC/RS) on sta-
tistical results (see supplementary table e2). Hazard 
ratios were extracted for every variability measure and 
outcome. The hazard ratio from the analysis with the 
greatest adjustment for confounders but containing 
only a single variability measure was extracted. Where 
required data were not available, we emailed the study 
authors.
Data analysis and statistical methods
Hazard ratios were converted to standardised hazard 
ratios, using a general method for regression models 
(see supplementary table e3).34 Briefly, a standardised 
log-hazard ratio was calculated as the log-hazard ratio 
for each unit of standardised blood pressure variability 
(blood pressure variability divided by its sample stan-
dard deviation). These were pooled using a random 
effects meta-analysis, stratified by outcome. Separate 
analyses were performed for each period of variability 
(long term, mid-term, or short term). Heterogeneity was 
assessed using the χ2 test and I2 statistic.
Where studies used multiple measures of variability, 
we included hazard ratios in analysis according to the 
following hierarchy (preferred to least preferred): 
 standard deviation, coefficient of variation, variation 
independent of mean, average real variability, stan-
dardised residual, root successive variance, and other. 
Where hazard ratios were calculated using data from 
the same primary study but reported in different papers, 
we included the most recently published hazard ratio. 
We combined the hazard ratios for study subgroups 
before inclusion.
Two reviewers (SS and RS) independently assessed 
the risk of bias using the QUIPS tool,35 with adjudica-
tion by a third reviewer (RM). We also extracted infor-
mation about other potential confounders, specific to 
studies of blood pressure variability (see supplemen-
tary table e2). Consistency of blood pressure measure-
ment with respect to device, cuff size, staff, and 
measurement is important to prevent inducing the vari-
ability. The impact of other potential confounders may 
be adjusted for during analyses. We decided (a priori) to 
include in main analyses only hazard ratios that were 
correctly adjusted for the equivalent mean blood pres-
sure level (eg, adjusted for mean daytime systolic blood 
pressure if variability was assessed for daytime systolic 
blood pressure), where outcome ascertainment took 
place after the blood pressure measurement period 
and, for studies involving antihypertensive treatment, 
where at least 80% of patients were adherent to treat-
ment or did not change drugs during the measurement 
period, or where patients were censored at the point of 
change of treatment. We carried out secondary analyses 
including all studies.
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Publication bias was assessed by Egger’s test.36  How-
ever, since this has low power for small numbers of 
studies, we also calculated the number of null effect 
studies of mean weight that would need to be included 
in meta-analyses to result in a non-significant pooled 
effect (known as fail-safe N).37
Patient involvement
Two lay representatives contributed to the design and 
content of the National Institute for Health Research 
programme grant from which this work arose. Results 
from this work have been presented as part of the wider 
programme at regular steering group meetings.
Results
Searches identified 5861 references. Removal of dupli-
cates and screening by two reviewers yielded 41 full text 
articles for inclusion (fig 1 ). These 41 papers repre-
sented 19 observational cohort studies and 17 clinical 
trial cohorts, and 46 separate analyses (see supplemen-
tary table e4). Twenty four papers10 14-16 18 19 38-55  studied 
long term variability (ie, monitoring of blood pressure 
in clinics), four56-59  studied mid-term variability (home 
monitoring), and 1510-13 41 60-69  studied short term vari-
ability (ambulatory monitoring). The number of partic-
ipants in each study ranged from 45741  to 122 63654  and 
follow-up ranged from 2514 person years41 to 490 544 
person years.54
study design and analysis characteristics
Consistency of blood pressure measurement with 
respect to cuff size, arm, device, and staff was unclear 
or had the potential to introduce variability (eg, mer-
cury sphygmomanometers and changing staff) in all of 
the 36 included studies (see supplementary table e5). 
Similarly, the potential for confounding was introduced 
because of the analysis (or this was unclear) in all 46 
separate analyses. Results from 23 analyses were 
excluded from our main analyses on the basis of the 
three prespecified criteria: eight analyses failed to cor-
rectly adjust for mean blood pressure, 15 did not 
account for major drug change during the measurement 
period, and 20 did not separate the measurement and 
follow-up periods. Results from four analyses (three 
studies) were not reported in sufficient detail to allow 
data extraction.
QuiPs risk of bias
Using QUIPS, most of the 46 analyses were rated at 
moderate risk of bias for study participation, often 
because of inclusion criteria based on blood pressure 
readings and a potential for regression to the mean 
effects (see supplementary table e6). Eighteen analyses 
were at high risk of bias because the measurement 
period for blood pressure variability was confounded 
by follow-up (n=17), and one analysis67 failed to report 
non-significant results. All of the analyses rated at high 
risk of bias using QUIPS were excluded from our main 
analysis based on the assessments in supplementary 
table e5.
Long term variability measured by clinic monitoring
Twenty four papers reported results from 27 studies that 
measured blood pressure variability in clinics (long 
term). Results from three studies44 48 52 were not pre-
sented in sufficient detail for extraction.
Eight studies examined long term variability in sys-
tolic blood pressure and all cause mortality, of which 
four had sufficiently low risk of bias to be included in 
the main analysis (fig 2, standardised hazard ratio 1.15, 
95% confidence interval 1.09 to 1.22). Heterogeneity 
between studies (I2=70.7%, P=0.02) was reduced after 
removal of a study in patients with previous stroke or 
vascular disease:43 this did not significantly alter the 
results (hazard ratio 1.12, 95% confidence interval 1.08 
to 1.16; I2=34.9%, P=0.21).
Three studies assessing blood pressure variability 
and cardiovascular disease mortality showed a 
Records identied through database search (n=5861)
Records screened (n=5852)
Full text articles assessed for eligibility (n=116)
Included in qualitative synthesis (n=41 papers; 36 studies)
Included in quantitative synthesis
(main or secondary analysis) (n=33 studies)
Duplicates (n=9)
Full text articles excluded (n=75):
  Not a full article (n=26)
  Not relevant (n=16)
  Insucient follow-up (n=9)
  Too few measurements (n=11)
  Review/comment piece (n=13)
Records excluded (n=5736)
fig 1 | study screening flowchart
Studies meeting methodological critieria
  Poortvliet51
  Hata43
  Suchy-Dicey18
  Muntner50
Subtotal: P=0.02, I2=70.7%
Studies not meeting methodological criteria
  McMullan49
  Lau16
  Hara42
  Gao15
Subtotal: P=0.002, I2=80.2%
Overall: P=0.00, I2=85.1%
1.10 (1.05 to 1.15)
1.29 (1.17 to 1.43)
1.11 (1.06 to 1.17)
1.18 (1.10 to 1.26)
1.15 (1.09 to 1.22)
1.61 (1.06 to 2.43)
1.23 (1.07 to 1.41) 
0.95 (0.82 to 1.10)
0.98 (0.93 to 1.02)
1.09 (0.93 to 1.27)
1.12 (1.05 to 1.20)
16.47
12.94
16.18
15.28
60.87
2.47
10.47
9.93
16.26
39.13
100.00
0.7 1 1.4 2.5
Study
Favours
increased
variability
Favours
decreased
variability
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
Weight
(%)
SD
SD
SR
SD
SD
CV
VIM
RMSE
Variability
measure
fig 2 | random effects meta-analysis of standardised hazard ratios for increases in clinic 
systolic blood pressure variability and all cause mortality. sD=standard deviation; 
sr=standardised residual; Cv=coefficient of variation; vim=variation independent of the 
mean; rmse=root mean squared error
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 significant relation (see supplementary figure e1, haz-
ard ratio 1.18, 95% confidence interval 1.09 to 1.28) but 
only a single study examining cardiovascular disease 
events was suitable for inclusion (see supplementary 
figure e2, 1.18, 1.07 to 1.30).
Fourteen studies reported results for stroke events, of 
which six were included in the main analysis (fig 3; 1.15, 
1.04 to 1.27; I2=82.1%, P<0.001). Results were similar 
after omission of the hazard ratio from the UK-TIA 
trial,70 which removed the heterogeneity (1.10, 1.05 to 
1.14; I2=0.0%, P=0.62).
Results for coronary heart disease events and myo-
cardial infarction showed similar results (see supple-
mentary figures e3 and e4). Across all outcomes, 
secondary analysis including results from all studies 
regardless of risk of bias did not alter results.
Mid-term variability measured by home monitoring
Four papers reported results from two studies that mea-
sured mid-term variability in home blood pressure 
monitoring. All four papers were of sufficient quality to 
be included in main analyses, but a lack of data from 
distinct studies meant it was only possible to perform 
formal meta-analysis for the all cause mortality out-
come. Variability in systolic blood pressure was a signif-
icant predictor of death when blood pressure was 
measured in the morning or evening, or both (fig 4, eg, 
hazard ratio for increases in combined blood pressure 
variability 1.15, 95% confidence interval 1.06 to 1.26). 
Study level results for other outcomes are given in sup-
plementary table e7).
Short term variability measured by ambulatory 
monitoring
Fifteen papers examined short term variability in 
ambulatory blood pressure in 11 distinct studies. 
We  were unable to include results from many 
studies,11 13 41 56 57 65-67 69 owing to overlap with two 
large studies (IDACO61 and ABP-International64), 
which combined results across cohorts.
Three studies examined daytime variability in sys-
tolic blood pressure and all cause mortality, of which 
two were included in the main analysis (fig 5; hazard 
ratio 1.10, 95% confidence interval 1.04 to 1.16). Four 
studies examined daytime variability in blood pressure 
and cardiovascular disease mortality, and analysis of 
three studies with low risk of bias showed a significant 
association (see supplementary figure e5, 1.12, 1.03 to 
1.21). Daytime blood pressure variability was also sig-
nificantly associated with increased risk of stroke (see 
supplementary figure e6; 1.11, 1.01 to 1.21). Results for all 
three outcomes were unchanged in secondary analysis 
including results from all studies.
No associations were found between variability in 
blood pressure and cardiovascular disease (see supple-
mentary figure e7) or coronary heart disease events (see 
supplementary figure e8), although results became sig-
nificant in secondary analyses. The supplementary file 
details the results for night-time and 24 hour systolic 
ambulatory blood pressure (see figures e9 to e18).
Publication bias
There was no evidence of publication bias for any 
outcome in relation to long term, mid-term, or short 
term variability in systolic blood pressure as judged by 
Egger’s test. Significant findings for clinic monitoring 
would remain unchanged for all outcomes even if at 
least 20 null effect studies were included in meta-
analyses, except for myocardial infarction where only a 
single null effect study would be required. Results for 
home monitoring would become non-significant after 
the addition of a single null effect study and those for 
variability in ambulatory blood pressure would become 
non-significant by the addition of between one and six 
null effect studies, depending on outcome and period of 
measurement.
discussion
This review has systematically assessed the literature 
for the association of long term (clinic monitoring), 
mid-term (home monitoring), and short term (ambula-
tory) variability in blood pressure with cardiovascular 
outcomes and mortality. Long term variability in mea-
surements is significantly associated with all cause and 
cardiovascular disease mortality, cardiovascular dis-
ease events, stroke, and myocardial infarction, inde-
pendent of mean blood pressure. Mid-term and short 
term variability are also associated with mortality, and 
limited data for other outcomes also broadly support an 
association with cardiovascular outcomes. Across all 
analyses (long term, mid-term, and short term), the haz-
ard ratios for coronary heart disease events were 
smaller than those for stroke, suggesting that the effect 
Studies meeting methodological critieria
  Rothwell (UK-TIA)10
  Poortvliet51
  Shimbo53
  Hata43
  Suchy-Dicey18
  Muntner50
Subtotal: P=0.00, I2=82.1%
Studies not meeting methodological criteria
  Rothwell (ASCOT-BPLA)10
  Rothwell (Dutch-TIA)10
  Rothwell (ESPS1)10
  Carr40
  Yu54
  Lau16
  Hara42
  Gao15
Subtotal: P=0.040, I2=52.3%
Overall: P=0.00, I2=77.7%
1.57 (1.37 to 1.79)
1.10 (0.99 to 1.23)
1.11 (1.05 to 1.17)
1.08 (0.93 to 1.25)
1.01 (0.91 to 1.13)
1.14 (1.02 to 1.28)
1.15 (1.04 to 1.27)
1.52 (1.26 to 1.83)
1.41 (1.15 to 1.73)
1.18 (1.06 to 1.32)
1.15 (1.01 to 1.31)
1.28 (1.23 to 1.33)
1.08 (0.87 to 1.34)
1.03 (0.83 to 1.27)
1.18 (0.97 to 1.44)
1.23 (1.14 to 1.32)
1.19 (1.11 to 1.27)
7.30
8.21
9.90
6.82
8.19
7.99
48.40
5.65
5.10
8.14
7.43
10.25
4.82
4.90
5.30
51.60
100.00
0.7 1 1.4 2.5
Study
Favours
increased
variability
Favours
decreased
variability
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
Weight
(%)
SD
SD
SD
SD
SR
SD
SD
SD
SD
SR
SD
CV
VIM
RMSE
Variability
measure
fig 3 | random effects meta-analysis of standardised hazard ratios for increases in 
clinic systolic blood pressure variability and stroke events. sD=standard deviation; 
sr=standardised residual; Cv=coefficient of variation; vim=variation independent of 
the mean; rmse=root mean squared error
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observed for cardiovascular disease events—as with 
mean blood pressure—may be driven primarily by cere-
brovascular events.
strengths in relation to the literature
This review includes over one million person years of 
data and combines the results from long, mid-term, and 
short-term blood pressure measurement, allowing com-
parison. We have addressed the methodological issues 
that are particular to research on variability in blood 
pressure and have shown that although there is now 
considerable evidence on this topic, most studies are of 
poor quality or poorly reported. By limiting our main 
analysis to studies that avoid potential sources of con-
founding, this review confirms that the apparent prog-
nostic value of blood pressure variability is a true 
prospective association and can be demonstrated even 
in studies with low risk of bias.
In this review we used standardised hazard ratios to 
overcome the diversity of measures for variability used 
in primary studies, and hence combined more data. For 
example, our meta-analysis for long term variability 
and stroke events includes 14 studies, more than double 
the number in previous analyses.24 25  This review also 
had sufficient data for meta-analysis of the effect of 
short term variability of blood pressure on outcomes, 
which was a limitation of a previous work.28
Finally, we demonstrated the robustness of results to 
possible unpublished null effect studies across long 
term, mid-term, and short term variability in blood 
pressure. Although results for long term variability may 
be considered conclusive, results for mid-term and 
short term variability are more susceptible to publica-
tion bias and may warrant further investigation.
limitations of this review
Included studies were primarily in older adults (mean 
age 48.5 to 77 years) and those at increased risk of car-
diovascular disease (eg, due to hypertension) and con-
ducted in European or East Asian populations. Hence 
the applicability of our findings to younger or healthier 
people and other ethnic groups is unknown. Studies in 
patients with a history of cerebrovascular events 
reported the largest hazard ratios, but significant asso-
ciations remained after removal of these studies from 
analyses, and so findings remain applicable to people 
free from cerebrovascular disease. In studies in hyper-
tensive patients,14 40 69  blood pressure variability could 
be confounded by entry criteria (regression to the 
mean)71 and treatment. However, such effects would 
diminish rather than exaggerate hazard ratios for vari-
ability, and so our overall conclusions are sound.
Lack of data from distinct cohorts prevented formal 
meta-analyses for many outcomes for to mid-term 
 variability in blood pressure. A previous review was 
similarly limited by paucity of data,26 despite broader 
inclusion criteria. Our meta-analyses for short term 
variability in blood pressure were also dominated by 
two large studies. Despite these caveats, results sup-
ported an effect of shorter term variability on cardiovas-
cular outcomes, and pooled hazard ratios were similar 
to those observed for long term variability. We were 
unable to determine if findings varied with timing and 
frequency of measurement.
In several analyses, there was significant heterogene-
ity between studies, potentially due to outlying studies 
in specific populations (eg, previous vascular disease) 
or to approximations necessary during data extraction, 
such as conversion from categorical (eg, from 10ths10  or 
thirds49) to continuous scale. However, not all con-
verted hazard ratios were outliers,50 and we verified our 
conversion method in simulated data (not shown). 
 Significant heterogeneity was reduced by removal of 
 outlier studies, but this did not significantly alter the 
results.
In some cases, few studies contributed to main 
analyses, and the validity of these meta-analyses is 
debateable. Secondary analysis utilising data from all 
studies regardless of quality greatly increased the 
amount of available data but did not materially 
change results. Only three otherwise eligible studies 
Morning
  Johansson58
  Asayama56
Subtotal: P=0.52, I2=0%
Evening
  Johansson58
  Asayama56
Subtotal: P=0.44, I2=0%
Combination
  Kikuya59
  Johansson58
Subtotal: P=0.88, I2=0%
1.21 (1.06 to 1.38)
1.15 (1.04 to 1.27)
1.17 (1.08 to 1.27)
1.17 (0.98 to 1.39)
1.08 (0.98 to 1.19)
1.10 (1.01 to 1.20)
1.15 (1.04 to 1.28)
1.17 (0.99 to 1.38)
1.15 (1.06 to 1.26)
34.66
65.34
100.00
24.15
75.85
100.00
71.74
28.26
100.00
0.7 1 1.4
Studies meeting
methodological
critieria
Favours
increased
variability
Favours
decreased
variability
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
Weight
(%)
SD
VIM
SD
VIM
SD
SD
Variability
measure
fig 4 | random effects meta-analysis of standardized hazard ratios for increases in home 
systolic blood pressure variability and all cause mortality. sD=standard deviation; 
vim=variation independent of mean
Studies meeting methodological critieria
  Hansen61
  Palatini64
Subtotal: P=0.85, I2=0%
Studies not meeting methodological criteria
  Mancia62
Subtotal
Overall: P=0.95, I2=0%
1.10 (1.04 to 1.17)
1.12 (0.97 to 1.28)
1.10 (1.04 to 1.16)
1.12 (0.99 to 1.27)
1.12 (0.99 to 1.27)
1.11 (1.05 to 1.16)
70.16
13.47
83.63
16.37
16.37
100.00
0.7 1 1.4
Study
Favours
increased
variability
Favours
decreased
variability
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
Weight
(%)
ARV
SD
SD
Variability
measure
fig 5 | random effects meta-analysis of standardised hazard ratios for increases in 
variability of ambulatory systolic blood pressure and all cause mortality. sD=standard 
deviation; arv=average real variability
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failed to contribute any quantitative data, despite 
contact with authors.44 48 52
In general, there was poor reporting of study factors 
that may confound the relation between blood pressure 
variability and outcomes. Although studies were 
excluded from main analyses based on the three most 
important factors (prespecified), it was not feasible to 
do this for all factors. Further adjustment for confound-
ers might be possible using individual patient data but 
was beyond the scope of this review. The importance of 
consideration and reporting of such confounding fac-
tors in future work on blood pressure variability (and 
variability in other biological measures) should be 
emphasised. Although our results indicate that these 
may be less important in the assessment of blood pres-
sure variability, they may prove instrumental in other 
clinical areas.
Clinical implications
The mechanism linking blood pressure variability to 
cardiovascular events is not well understood. Short 
term variability in blood pressure is affected by 
behavioural, emotional, and postural influences on car-
diovascular physiology and cardiac rhythm.72 73  Arterial 
stiffness contributes to both short term74 75  and long 
term variability in blood pressure.73 76 77  Meanwhile, 
poor control of blood pressure resulting in changes to 
antihypertensive drugs also affects variability.72  Use of 
certain classes of antihypertensive drugs has also been 
linked with increased visit-to-visit variability78  and may 
not be entirely explained by adherence.79
The estimated standardised hazard ratio for the effect 
of long term variability in blood pressure on cardiovas-
cular disease mortality was 1.18. For comparison, the 
effect of mean blood pressure on cardiovascular disease 
mortality reported in a previous meta-analysis3  corre-
sponds to a standardised hazard ratio of approximately 
1.7 (assuming a between person standard deviation of 
15 mm Hg). Note that the latter standardised hazard 
ratio for mean blood pressure is not adjusted for vari-
ability, whereas the former (for blood pressure variabil-
ity) is adjusted for mean blood pressure, showing the 
additional prognostic value of variability over and 
above the mean. This supports the results of recent 
work showing the improved discrimination of models 
including short term night-time variability in blood 
pressure64  or long term variability,39 over and above tra-
ditional risk factors.
How does blood pressure variability compare with 
other risk factors for cardiovascular disease? A recent 
review80 found that the adjusted standardised hazard 
ratio for increases in cholesterol on cardiovascular dis-
ease events varied between 1.16 and 1.29 in primary 
 prevention groups, depending on the measure of cho-
lesterol considered (eg, total cholesterol, triglycerides). 
Hence variability in blood pressure has similar prog-
nostic value to cholesterol measures (standardised haz-
ard ratio for long term variability on cardiovascular 
disease events=1.18).
Variability in blood pressure is not easily assessed 
clinically, and it is unclear if certain measures of 
 variability should be preferred. Some measures could 
be calculated by hand (eg, average real variability), 
whereas others could be automatically calculated by 
electronic health records. This would enable doctors to 
account for both mean and variability in blood pressure 
concurrently when assessing cardiovascular risk. For 
example, assuming a standard deviation for variability 
(standard deviation) in systolic blood pressure of 
5 mm Hg, an individual with variable blood pressure 
readings (139, 132, and 125 mm Hg, mean 132, SD 7) 
could be considered at 18% greater risk of cardiovascu-
lar disease events than a similar person with stable 
blood pressure (134, 130, and 132 mm Hg, mean 132, SD 
2). This may be particularly important for patients with 
a highly variable but comparatively low mean blood 
pressure or for whom traditional cardiovascular risk 
estimates lie close to treatment thresholds. Further 
work is needed to determine the feasibility of obtaining 
such additional information, and the clinical impact on 
subsequent risk management.
Conclusion
Long term variability in blood pressure measured in 
adults at clinic visits is associated with cardiovascular 
and mortality outcomes, over and above the effect of 
mean blood pressure. Mid-term (home monitoring) 
and short term (ambulatory monitoring) variability in 
blood pressure is also associated with all cause mor-
tality, but the association with cardiovascular disease 
outcomes requires further investigation in novel 
cohorts.
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